Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03878524 · ClinicalTrials.gov registry record · Phase 1
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
A Phase 1 study, sponsored by OHSU Knight Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT03878524: Clinical Trial Phase 1 study, sponsored by OHSU Knight Cancer Institute.
NCT03878524 is a Phase 1 study that was terminated before completion, run by OHSU Knight Cancer Institute. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03878524, a Phase 1 study, was terminated before completion, sponsored by OHSU Knight Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has. This study is also being done to understand why cancer drugs can stop working and how different cancers in different people respond to different types of therapy.
Primary Outcome
Measured as the number of participants to receive the first dose of Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART)-PRIME therapy (Therapy #1) within 3 months from the date of Clinical Tumor Board providing a recommended drug combination.
Interventions
- DRUG Abemaciclib
- DRUG Abiraterone
- DRUG Afatinib
- BIOLOGICAL Bevacizumab
- DRUG Bicalutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-04-01 |
| Est. Completion | 2020-12-10 |
| Phase | Phase 1 |
Why NCT03878524 stopped before completion
NCT03878524 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 5 interventions - of which Abemaciclib is the first listed.
NCT03878524 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03878524 about?
NCT03878524 is a clinical study titled "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial". This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has. This study is also being done to understand why cancer drugs can stop working and how different cancers in different peo...
What is the current status of trial NCT03878524?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2020-04-01. Estimated completion is 2020-12-10.
What interventions are being tested in trial NCT03878524?
The interventions under investigation include: Abemaciclib (DRUG), Abiraterone (DRUG), Afatinib (DRUG), Bevacizumab (BIOLOGICAL), Bicalutamide (DRUG).
Who is sponsoring clinical trial NCT03878524?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03878524's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI